Cidara Therapeutics Net Debt Over Time
| CDTX Stock | USD 20.40 2.95 16.91% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cidara Therapeutics Performance and Cidara Therapeutics Correlation. Cidara |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cidara Therapeutics. If investors know Cidara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cidara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (23.90) | Revenue Per Share 11.875 | Quarterly Revenue Growth (0.94) | Return On Assets (0.16) | Return On Equity (1.53) |
The market value of Cidara Therapeutics is measured differently than its book value, which is the value of Cidara that is recorded on the company's balance sheet. Investors also form their own opinion of Cidara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cidara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cidara Therapeutics' market value can be influenced by many factors that don't directly affect Cidara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cidara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cidara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cidara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Debt Analysis
Compare Cidara Therapeutics and related stocks such as CytomX Therapeutics, ContraFect Corp, and Clearside Biomedical Net Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTMX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (61.4 M) | (59.8 M) | (104.6 M) | (177.5 M) | (247.6 M) | (163.6 M) | (167 M) | (187.5 M) | (175.6 M) | (3.2 M) | (3.4 M) |
| CLSD | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (8.3 M) | (14.3 M) | (27.2 M) | (1.2 M) | 1.9 M | (16.2 M) | (15.3 M) | (29.8 M) | (47 M) | 14.1 M | 14.8 M |
| GLYC | (28.2 M) | (28.2 M) | (17.4 M) | (2.3 M) | (55.2 M) | (46.8 M) | (40 M) | (123.9 M) | (209.9 M) | (154.6 M) | (134.2 M) | (88.3 M) | (47 M) | (41 M) | (43 M) |
Cidara Therapeutics and related stocks such as CytomX Therapeutics, ContraFect Corp, and Clearside Biomedical Net Debt description
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.My Equities
My Current Equities and Potential Positions
| Cidara Therapeutics | CDTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 20.4
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.